Patents Assigned to Hoffmann-La Roche Inc.
  • PROTEASE-ACTIVATED POLYPEPTIDES
    Publication number: 20240376171
    Abstract: The present invention generally relates to novel isolated polypeptides and immunoconjugates and their uses. The polypeptides and immunoconjugates comprise at least one protease recognitions sequence, which is a substrate for matriptase.
    Type: Application
    Filed: March 28, 2022
    Publication date: November 14, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Samuele CALABRO, Peter BRUENKER, Linda FAHRNI, Anne FREIMOSER-GRUNDSCHOBER, Martina GEIGER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Evelyn SAUER, Pablo UMAÑA, Inja WALDHAUER
  • TARGETED INTERFERON ALPHA FUSION PROTEINS AND METHODS OF USE
    Publication number: 20240376205
    Abstract: The invention provides fusion proteins that comprise a human IFN-?2, a first antigen-binding domain capable of binding to human PD-L1, a second antigen-binding domain capable of binding to human PD-L1 and to human IFN-?2, and methods of using the same.
    Type: Application
    Filed: May 7, 2024
    Publication date: November 14, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jack Anthony BATES, Davide BERTOLDO, Ulrich BRINKMANN, Harald DUERR, Moritz RAPP, Jasmin SYDOW-ANDERSEN, Pablo UMAÑA, Monika WOLF
  • PURIFICATION OF ANTIBODIES BY MIXED MODE CHROMATOGRAPHY
    Publication number: 20240376146
    Abstract: Herein is reported a method for producing or purifying an antibody using a mixed mode chromatography material that comprises ion exchange functional groups and hydrophobic interaction functional groups (MM HIC/TEX) operated in flowthrough mode, wherein the antibody is a hydrophilic antibody, and the antibody is applied in a solution comprising the antibody and an antichaotropic salt to the MM HIC/IEX chromatography material.
    Type: Application
    Filed: September 29, 2023
    Publication date: November 14, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Roberto FALKENSTEIN, Susanne KONRAD
  • QUATERNARY AMMONIUM CATION SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS
    Publication number: 20240376073
    Abstract: The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as described herein: Frther provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.
    Type: Application
    Filed: January 4, 2024
    Publication date: November 14, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Sandra Marie Joseph GRALL-ULSEMER, Xingchun HAN, Joel Lukas KNECHT, Christian LERNER, Mingming LI, Yongqiang LIU, Patrizio MATTEI, Matthias NETTEKOVEN, Philippe PFLIEGER, Theodor STOLL, Jianhua WANG, Min WANG, Yongguang WANG, Song YANG, Chengang ZHOU
  • Process for the preparation of GalNAc phosphoramidite epimers
    Patent number: 12139506
    Abstract: The invention comprises a process for the preparation of a GalNAc phosphoramidite epimer of the formula (I), wherein R1 is a hydroxy protecting group, n is an integer from 0 to 10 and m is an integer from 0 to 20, corresponding enantiomers and/or optical isomers thereof and the use of the process for the preparation of GalNAc-cluster oligonucleotide conjugates.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: November 12, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Simon Adolf Breitler, Kurt Puentener
  • T cell activating bispecific antigen binding molecules
    Patent number: 12139553
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target 511cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: January 20, 2022
    Date of Patent: November 12, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Peter Bruenker, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Pablo Umana, Tina Weinzierl
  • USE OF QUINAZOLINONE COMPOUND FOR THE TREATMENT OF CANCER
    Publication number: 20240366605
    Abstract: The present invention is directed to (3R)—N—[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, wherein the patient suffering from said cancer was previously under treatment with a different BRAF inhibitor.
    Type: Application
    Filed: May 3, 2024
    Publication date: November 7, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ester BONFILL TEIXIDOR, Raffaella IURLARO, Piergiorgio Francesco Tommaso PETTAZZONI, Juan SEOANE SUÁREZ, Juergen WICHMANN
  • HETEROCYCLIC COMPOUNDS
    Publication number: 20240368117
    Abstract: The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein X, D, R1 to R4, and R6 to R10 are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.
    Type: Application
    Filed: November 10, 2023
    Publication date: November 7, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Mathis BRAENDLIN, Sandra Marie Joseph GRALL-ULSEMER, Xingchun HAN, Christian LERNER, Mingming LI, Yongqiang LIU, Sébastien SCHMITT, Jianhua WANG, Yongguang WANG, Min WANG, Song YANG, Chengang ZHOU
  • AGONISTIC CD28 ANTIGEN BINDING MOLECULES TARGETING EPCAM
    Publication number: 20240368309
    Abstract: The present invention relates to bispecific agonistic CD28 antigen binding molecules characterized by monovalent binding to CD28 comprising new humanized EpCAM antibodies, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
    Type: Application
    Filed: December 1, 2023
    Publication date: November 7, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stephan GASSER, Guy GEORGES, Thomas HOFER, Christian KLEIN, Ekkehard MOESSNER, Johannes SAM, Jenny Tosca THOM, Pablo UMANA, Tina WEINZIERL
  • BENZIMIDAZOLE PYRIDINE DERIVATIVES
    Publication number: 20240366581
    Abstract: The invention relates to a compound of formula (I) wherein A1, R1, R2, R3, R4 and R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament for treatment of indications associated with Salt-inducible kinases (SIK) such as of rheumatoid arthritis, juvenile rheumatoid arthritis, non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis, giant cell vasculitis, inflammatory bowel diseases (IBD), atherosclerosis, type 2 diabetes or glomerulonephritis.
    Type: Application
    Filed: July 18, 2024
    Publication date: November 7, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Katrin GROEBKE ZBINDEN, Wolfgang HAAP, Lukas KREIS, Kin-Chun Thomas LUK, Steven Gregory MISCHKE, Philippe PFLIEGER
  • BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER
    Publication number: 20240368150
    Abstract: The present invention provides new bicyclic tetrahydroazepine derivatives having the general formula (I), wherein X, Y, R1, R2, R3, R4, R5, R6, R6a are as defined herein, compositions including the compounds, processes of manufacturing the compounds and methods of using them in the treatment of cancer.
    Type: Application
    Filed: February 10, 2022
    Publication date: November 7, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Adrian BRITSCHGI, Roman HUTTER, Holger KUEHNE, Bernd KUHN, Thomas LUEBBERS, Laetitia Janine MARTIN, Barbara Johanna MUELLER, Juergen WICHMANN, Marco BRANDSTAETTER
  • Syringe pack and method of packing a prefilled syringe
    Patent number: 12133963
    Abstract: A syringe pack with a prefilled syringe (1) and a packaging (2) comprises: a barrel part (11) with an orifice (113) at a proximal end and a flange portion (112) at a distal end; a plunger part (13) extending through the distal end of the barrel part (11) into the barrel part (11); a stopper (12) adjacent to a proximal end of the plunger part (13) and arranged inside the barrel part (11) such that a dosage chamber (111) is formed inside the barrel part (11); and a drug substance arranged inside the dosage chamber (111), wherein the prefilled syringe (1) is arranged in the packaging (2) and the packaging (2) is configured to allow external sterilization of the prefilled syringe (1) arranged in the packaging (2).
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: November 5, 2024
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Richard Dumont, Neil B. Cammish, Markus Hemminger, Cyrille Blintz, Flora Felsovalyi
  • Solid forms
    Patent number: 12134599
    Abstract: The disclosure is in part directed to crystalline forms of 5-(3,4-dichlorophenyl)-N-((1R,2R)-2-hydroxycyclohexyl)-6-(2,2,2-trifluoroethoxy)nicotinamide and pharmaceutical compositions thereof.
    Type: Grant
    Filed: October 11, 2023
    Date of Patent: November 5, 2024
    Assignees: River 3 Renal Corp., Hoffmann-La Roche Inc.
    Inventors: He Hongyan, Jiang Siyi, Urs Schwitter, Pascal Jean Claude Dott, Ralph Diodone, Nicole Wyttenbach, Olaf Grassmann
  • PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE
    Publication number: 20240360126
    Abstract: The present invention relates to compounds of formula (I), wherein R1 to R3, A, M, W and Q are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: March 15, 2024
    Publication date: October 31, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Dongdong Chen, Fabian Dey, Xin Hong, Xiaoqing Wang, Zhisen Zhang, Wei Zhu, Ge Zou
  • COMBINED ADMINISTRATION
    Publication number: 20240358704
    Abstract: The invention relates to 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one, also known as risdiplam, for use in the treatment of spinal muscular atrophy (SMA) with GYM329, its pharmaceutical composition to be used in the treatment of SMA, its methods of treatment thereof.
    Type: Application
    Filed: April 5, 2024
    Publication date: October 31, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Nicole HELLBACH, Heidemarie KLETZL, Friedrich METZGER, Renata SICILIANI SCALCO
  • BISPECIFIC ANTI-CCL2 ANTIBODIES
    Publication number: 20240360208
    Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.
    Type: Application
    Filed: December 8, 2023
    Publication date: October 31, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guy GEORGES, Jens FISCHER, Lukasz KACPRZYK, Valeria RUNZA, Jasmin SYDOW-ANDERSEN, Cristina BERTINETTI-LAPATKI, Michael GERTZ, Shu FENG, Siok Wan GAN, Wei Shiong Adrian HO, Runyi Adeline LAM
  • Adjuvant treatment of HER2-positive breast cancer
    Patent number: 12128103
    Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.
    Type: Grant
    Filed: April 16, 2024
    Date of Patent: October 29, 2024
    Assignees: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Mark C. Benyunes, Graham Alexander Ross
  • Process for the preparation of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8- dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives
    Patent number: 12122791
    Abstract: The present invention relates to a process for the preparation of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives useful as pharmaceutically active compounds.
    Type: Grant
    Filed: June 16, 2022
    Date of Patent: October 22, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jean-Michel Adam, Serena Maria Fantasia, Daniel Vincent Fishlock, Fabienne Hoffmann-Emery, Gerard Moine, Christophe Pfleger, Christian Moessner
  • Forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making
    Patent number: 12122789
    Abstract: The present invention relates to a process for the preparation of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one useful as pharmaceutically active compounds.
    Type: Grant
    Filed: April 16, 2021
    Date of Patent: October 22, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Roland Meier, Urs Schwitter, Anne De Paepe, Juergen Thun, Frank Stowasser
  • E3 UBIQUITIN LIGASE (UBE3A) PROTEIN TARGETS
    Publication number: 20240345097
    Abstract: The invention relates to UBE3A protein targets and their usage as target engagement biomarkers for compounds that modulate ube3a expression.
    Type: Application
    Filed: February 14, 2024
    Publication date: October 17, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ravi JAGASIA, Thomas KREMER, Sonja MEIER, Nikhil Janak PANDYA, Stefka Grigorova TYANOVA